Vericel (VCEL) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Vericel Corporation  (NASDAQ: VCEL)

Vericel's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Vericel in the second quarter 2026?
Vericel Corporation achieved a return on average equity (ROE) of 6.91 % in its second quarter 2026 a new company high.

ROE has advanced compared to 6.41% in the first quarter 2026, due to net income growth.

Within the Biotechnology & Pharmaceuticals industry 13 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 1805 to 1843.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change 20.61 % 20.56 % 21.47 % 25.01 % -
Y / Y Net Income Change - - 17.35 % - -
Net Income (TTM) in Millions 24 21 17 13 7
Return On Equity (TTM) 6.91 % 6.41 % 5.17 % 4.3 % 2.47 %
VCEL's Total Ranking # 1843 # 1805 # 1488 # 1716 # 1873
Equity (TTM) in Millions 370 356 355 322 307
Seq. Equity Change 3.88 % 0.45 % 10.19 % 4.91 % 3.83 %
Seq. Net Income Change - - 358.08 % - -

Back to VCEL Management Effectiveness >> VCEL's 5 Years Annual ROE >> Compare VCEL ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 14
Sector # 160
Overall # 1843

Return On Equity Statistics
High Average Low
6.91 %
-38.31 %
-411.01 %
(Jun 30 2026)   (Jun 30 2014)





VCEL Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 355 292 226 192 170
Y / Y Equity Change 21.47 % 29.22 % 17.52 % 12.79 % 26.96 %
Net Income in Millions 17 10 -3 -17 -7
Y / Y Net Income Change 59.41 % - - - -
Return On Equity 4.66 % 3.55 % -1.41 % -8.69 % -4.38 %

Back to VCEL Management Effectiveness >> VCEL's 5 Years Annual ROE >> Compare VCEL ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 4.66 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
VCEL's' Return on Equity at Yahoo Finance
VCEL's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for VCEL's Competitors
Subscribers only: Roe for Vericel's Suppliers
Subscribers only: Return On Equity for VCEL's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Brightspring Health Services Inc   18.93 %
Sbc Medical Group Holdings Incorporated  18.69 %
West Pharmaceutical Services Inc   18.51 %
Intuitive Surgical Inc   17.82 %
Standard Biotools Inc   17.64 %
Inspire Medical Systems inc   17.62 %
Medinotec Inc   17.47 %
Lemaitre Vascular Inc   16.93 %
Ufp Technologies Inc   16.72 %
Ensign Group Inc  16.53 %
Stryker Corp  16.36 %
Nephros Inc   16.20 %
Spero Therapeutics Inc   16.17 %
Progyny Inc   15.98 %
Collegium Pharmaceutical Inc   15.96 %
Alpha Pro Tech Ltd   15.43 %
Livanova Plc  15.41 %
Biolife Solutions Inc   15.28 %
Lifevantage Corp  15.06 %
Quest Diagnostics Inc  14.85 %
Infusystem Holdings Inc  14.81 %
Boston Scientific Corporation  14.77 %
Strata Critical Medical Inc   14.27 %
Beone Medicines Ltd   14.24 %
Royalty Pharma Plc  13.82 %
Regeneron Pharmaceuticals Inc   13.81 %
National Healthcare Corp  13.11 %
Kewaunee Scientific Corporation  12.61 %
Protagonist Therapeutics inc   11.80 %
Entrada Therapeutics Inc   11.77 %

Date modified: 2026-09-12T19:01:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.